Business Wire

Rivian Appoints Dr. Kjell Gruner as Chief Commercial Officer and President, Business Growth

1.9.2023 16:05:00 EEST | Business Wire | Press release

Share

Rivian Automotive, Inc. (NASDAQ: RIVN) today announced it has appointed Dr. Kjell Gruner as its Chief Commercial Officer and President, Business Growth. Gruner is joining Rivian from Porsche Cars North America, Inc. (PCNA), where he was most recently President and CEO. Gruner starts at Rivian today and will report directly to Rivian Founder and CEO RJ Scaringe. At Rivian, Gruner will oversee Rivian’s commercial function including Sales, Marketing, Customer Care, Delivery, Service, and Fleet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230901891588/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Rivian appoints Dr. Kjell Gruner as Chief Commercial Officer and President, Business Growth (Photo: Business Wire)

Dr. Kjell Gruner brings with him 25 years of automotive experience, having spent time at both Porsche and Daimler/Mercedes-Benz. Prior to joining PCNA, Gruner was the Global Vice President Marketing and Chief Marketing Officer for Porsche, where he oversaw the development of the global Porsche brand, marketing and product. Gruner also spent more than six years at Daimler where he was the Director of Strategy for Mercedes-Benz Cars, and he worked for two years at the Boston Consulting Group.

Gruner serves on the board of Livewire, the electric motorcycle manufacturer, The German American Chamber of Commerce of the Southern United States, Inc., and The Metro Atlanta Chamber of Commerce and is a member of the board of trustees at the Woodruff Arts Center.

RJ Scaringe, Founder and CEO, Rivian, said:
“We are very happy to welcome Kjell to the Rivian team as Chief Commercial Officer and President, Business Growth. We will rely on Kjell’s talent and experience as we position ourselves for growth domestically and internationally, the launch of a new platform in R2 at a new facility, and the continued success of our commercial vehicle line. I look forward to working closely together as we tackle this next great wave of opportunity.”

Dr. Kjell Gruner, Chief Commercial Officer and President, Business Growth, Rivian said:
“I am excited to join Rivian at this important time in its success story. Rivian has built an exceptional brand with two incredible consumer vehicles, the R1T and R1S, as well as category-defining commercial vans, at its core. As we build a strong brand, I look forward to chart paths into new markets, build new partnerships and customer experiences, and engage with our community while constantly embracing a clear and consistent strategy for the future.”

About Rivian:

Rivian (NASDAQ: RIVN) exists to create products and services that help our planet transition to carbon neutral energy and transportation. Rivian designs, develops, and manufactures category-defining electric vehicles and accessories and sells them directly to customers in the consumer and commercial markets. Rivian complements its vehicles with a full suite of proprietary, value-added services that address the entire lifecycle of the vehicle and deepen its customer relationships. Learn more about the company, products, and careers at www.rivian.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Harry Porter - media@rivian.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 14:02:00 EEST | Press release

SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 14:01:00 EEST | Press release

Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye